{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-011986","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2025-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.905471+00:00","generated_at":"2026-05-23T15:16:27.605992+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Windtree Therapeutics FY2024 net loss $1.8M; cash $1.8M; pivots to revenue-generating acquisitions","bullets":["Net loss $1.8M vs $20.3M in 2023; loss per basic share $104.35 on $5.5M net loss attributable to common.","Cash and equivalents $1.8M at Dec 31, 2024; raised ~$2.3M post-period, funding operations only through April 2025.","New corporate strategy: use equity to acquire small biotech firms with FDA-approved products; signed Evofem deal for PHEXXI distribution.","Positive Phase 2 SEISMiC Extension for istaroxime in early cardiogenic shock; SEISMiC C trial enrolling, interim data in Q3 2025.","R&D spend rose to $16.3M from $8.3M, driven by $7.5M Varian IPR&D charge and increased istaroxime development costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-011986","json":"https://secwatch.observer/filing/0001437749-25-011986.json","markdown":"https://secwatch.observer/filing/0001437749-25-011986.md","text":"https://secwatch.observer/filing/0001437749-25-011986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774925011986/0001437749-25-011986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774925011986/wint20241218_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:16:27.605992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}